*Actual product packaging may differ from the image shown.
PT-141 + Oxytocin (Oral Gummy)
Shop All Treatments
PT-141 + Oxytocin Gummy: Desire and Connection in One Lozenge
A discreet oral gummy combining the brain’s desire pathway with the bonding hormone behind emotional connection.
This combination gummy pairs PT-141 (bremelanotide), which acts on the brain’s desire pathways, with oxytocin, often called the bonding hormone for its role in trust, closeness, and emotional connection. Taken before anticipated intimacy, the combination targets both desire and emotional engagement in a discreet, needle-free format. The active bremelanotide is FDA-approved for hypoactive sexual desire disorder in premenopausal women; use for other patient groups, including men, is off-label.
Physician-prescribed · Compounded by licensed US pharmacies · On-demand dosing · Ongoing care team support
Bremelanotide (PT-141, Melanocortin-4 Receptor Agonist): Bremelanotide is a synthetic peptide that activates MC4 receptors in the hypothalamus, a region of the brain involved in the neural circuitry of sexual desire. By acting upstream of the vascular response, it can produce both increased subjective desire and improved physical response, particularly for people whose primary issue is low libido rather than mechanical erectile function. Onset is typically 45 minutes after the dose, with effects lasting several hours.
Oxytocin (Bonding Hormone): Oxytocin is a peptide hormone naturally released during intimacy, eye contact, and skin contact. It supports feelings of closeness, trust, and emotional bonding. When given as part of a sexual wellness protocol, oxytocin can amplify the emotional dimension that’s often inseparable from physical desire.
Best for: Adults seeking to address both desire and emotional engagement during intimacy, who would prefer an oral format over an injection.
Not recommended for: Anyone with uncontrolled hypertension or known cardiovascular disease (bremelanotide can transiently raise blood pressure), pregnant individuals, and people with a history of severe melasma or skin pigmentation concerns. Also not appropriate if you don’t have stable blood pressure readings.
Most common side effects are nausea (most pronounced with bremelanotide, often improving after the first one to two doses), flushing, headache, and a transient blood pressure increase. Less common: focal hyperpigmentation with repeated use. The active ingredient bremelanotide is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. Use for other patient groups, including men, is off-label and prescribed at physician discretion.
¹ About 59% of women reported a meaningful benefit; sexual desire improved significantly vs placebo (RECONNECT) Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology, 2019;134(5):899-908. → PubMed
² Significantly reduced sex-related distress vs placebo Kingsberg SA, et al. RECONNECT (same source as ¹). Supporting long-term data: Simon JA, et al. Obstetrics & Gynecology, 2019;134(5):909-917. → PubMed
³ Acts on the brain’s desire pathway (central melanocortin mechanism) Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine, 2007;4 Suppl 4:269-279. → PubMed
⁴ Oxytocin: increased orgasm intensity and contentment after intimacy Behnia B, Heinrichs M, Bergmann W, et al. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Hormones and Behavior, 2014;65(3):308-318. (In 29 couples, intranasal oxytocin increased the intensity of orgasm and contentment after sexual intercourse.) → PubMed
How it Works With EHRX
The entire process is online. No waiting rooms. Just straightforward, medically guided care.
Step 1
Choose your treatment and complete checkout
You'll receive a confirmation email with next steps.
Step 2
Complete a brief medical consultation
Check your email for a link to a short intake form and link to a virtual consult with a licensed physician.
Step 3
A licensed provider reviews your consultation
If approved, your prescription is written and sent to the pharmacy. If not, you receive a full refund.
Step 4
Your pharmacy ships within 3–5 business days
Your medication is shipped directly to your door in temperature-controlled packaging.
What to know before you start.
PT-141 + Oxytocin (Oral Gummy) is a compounded medication prepared by a licensed pharmacy for individual patient use.
It has not been reviewed by the FDA for safety or efficacy, and is prescribed based on the clinical judgment of a qualified healthcare provider. Compounded drugs are permitted to be prescribed but are not FDA-approved for safety and efficacy.
Clinical Evidence
Bremelanotide received FDA approval in 2019 (as Vyleesi) based on the RECONNECT Phase 3 trials, in which more than 1,200 premenopausal women with hypoactive sexual desire disorder showed statistically significant improvements in sexual desire and reduced distress versus placebo. Oxytocin’s role in bonding and intimacy is established but its clinical use in sexual wellness combinations is supported by smaller studies. (Source: Kingsberg et al., Obstetrics & Gynecology, 2019)
Frequently Asked Questions
We aim to provide absolute clarity regarding your biological data and personalized wellness protocols.
About 45 minutes before anticipated intimacy. Maximum one dose per 24 hours and no more than 8 doses per month.
Sildenafil and tadalafil improve blood flow. This combination targets the brain’s desire pathway and the emotional bonding pathway. The two approaches can be complementary.
Nausea is the most common early side effect with PT-141, usually mild and improving after the first one to two doses. A warming or flushing sensation is also common.
The active bremelanotide is FDA-approved (as Vyleesi) for premenopausal women with HSDD. Use in men is off-label and at physician discretion.
Yes. Baseline blood pressure is required, and self-monitoring during the first weeks is recommended.
You won’t be charged for the medication.
No. Compounded sexual wellness medications are paid out of pocket.
Yes, at any time before your next shipment, with no long-term commitment.
Initial check-in at 4 to 6 weeks, with ongoing access to your care team.
Sometimes, under provider guidance. Combinations require additional cardiovascular review.
Contact your care team. Dose adjustments or timing changes often resolve these.
The next generation
of weight management.
Dual-incretin metabolic support — personalized to you.
